Teva Pharmaceutical Industries Ltd. (TEVA) financials: revenue, earnings and cash flow
Fiscal 2019–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Teva Pharmaceutical Industries’s revenue went from $16.9B in fiscal 2019 to $17.3B in fiscal 2025, growth of about 0.4% a year.
Net income in fiscal 2025 was $1.4B, a net margin of 8.2%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $17.2B and net income $506M.
Free cash flow was $1.1B in fiscal 2025 and positive in 7 of the 7 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.2B | $17.3B | $16.5B | $15.8B | $14.9B | $15.9B | $16.7B | $16.9B |
| Gross profit | $9.2B | $8.9B | $8.1B | $7.6B | $7.0B | $7.6B | $7.7B | $7.5B |
| Operating income | $1.4B | $2.2B | -$303M | $433M | -$2.2B | $1.7B | -$3.6B | -$443M |
| Net income | $506M | $1.4B | -$1.6B | -$559M | -$2.4B | $417M | -$4.0B | -$999M |
| EPS (diluted) | $0.43 | $1.21 | $-1.40 | $-0.48 | $-2.10 | $0.36 | $-3.42 | $-0.86 |
| R&D | $1.8B | $1.0B | $998M | $953M | $98M | $967M | $997M | $1.0B |
| Revenue growth | — | +4.3% | +4.4% | +6.2% | −6.0% | −4.7% | −1.4% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.8B | $1.6B | $1.2B | $1.4B | $1.6B | $798M | $1.2B | $748M |
| Capital spending | -$534M | -$501M | -$498M | -$526M | -$548M | -$562M | -$578M | -$525M |
| Free cash flow | $1.2B | $1.1B | $749M | $842M | $1.0B | $236M | $638M | $223M |
| Dividends paid | — | — | — | — | — | — | — | — |
| Buybacks | — | — | — | — | — | — | — | — |
| Stock-based pay | $172M | $157M | $123M | $121M | $124M | $119M | $129M | $119M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash | — | $3.6B | $3.3B | $3.2B | $2.8B | $2.2B | $2.2B | $2.0B |
| Debt | — | $17.2B | $18.2B | $20.3B | $21.7B | $23.6B | $26.1B | $27.0B |
| Equity | — | $7.9B | $5.4B | $7.5B | $7.8B | $10.3B | $10.0B | $14.0B |
| Total assets | — | $40.7B | $39.3B | $43.5B | $44.0B | $47.7B | $50.6B | $57.5B |
| Shares (diluted) | 1.18B | 1.17B | 1.17B | 1.17B | 1.17B | 1.17B | 1.17B | 1.17B |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 53.5% | 51.8% | 48.7% | 48.2% | 46.7% | 47.8% | 46.4% | 44.6% |
| Operating margin | 8.3% | 12.5% | -1.8% | 2.7% | -14.7% | 10.8% | -21.4% | -2.6% |
| Net margin | 2.9% | 8.2% | -9.9% | -3.5% | -16.4% | 2.6% | -23.9% | -5.9% |
| FCF margin | 7.2% | 6.7% | 4.5% | 5.3% | 7.0% | 1.5% | 3.8% | 1.3% |
| ROIC | — | 6.8% | -1.0% | 1.5% | -5.9% | 3.4% | -9.5% | -0.8% |
| ROE | — | 17.8% | -30.5% | -7.4% | -31.3% | 4.1% | -39.8% | -7.1% |
Frequently asked questions
What is Teva Pharmaceutical Industries’s annual revenue?
$17.3B in fiscal 2025 and $17.2B over the twelve months to September 30, 2026.
How much profit does Teva Pharmaceutical Industries make?
Net income was $1.4B in fiscal 2025 (net margin 8.2%).
Is Teva Pharmaceutical Industries’s revenue growing?
Yes: revenue rose 4.3% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.